You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at S&P Capital IQ Pro or S&P Capital IQ .
Rexahn to raise $10M in registered direct offering
S&P Capital IQ Pro | Unrivaled Sector Coverage
S&P Capital IQ Pro | Powering Your Edge
Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud
Investment Research Analysts Providing Greater Coverage on Inflation
Rexahn Pharmaceuticals Inc. announced a $10 million registered direct offering with institutional investors to advance three anti-cancer compounds: RX-3117, Supinoxin and Archexin.
The company will issue 3,030,000 shares priced at $3.30 apiece, complete with warrants to buy up to an additional 1,520,000 shares for $4 per share within five years from the date of issue.
Rodman & Renshaw is the exclusive placement agent for the offering, which is expected to close by June 12.